Merck & Co., Inc.
CIK 310158 · View on SEC EDGAR ↗
- Portfolio value
- $526.4M
- Positions
- 13
- As of
- June 30, 2026
Portfolio value QoQ: +50.6% 13F does not disclose cash
- Top 10 holdings weight
- 99.79%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 8
- Effective number of positions
- 3.9
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 0.01% Est. buys $25,610,536 · sells $47,880
Median holding: 5.5 quarters Tracked Q4 2024–Q2 2026 · 65.0% still held
- New positions
- 3
- Increased
- 0
- Decreased
- 0
- Closed
- 1
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
- Related The person behind this filer, where we can match one.
Performance vs S&P 500
Annualized: +77.2% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 92.6% · Options excluded: 0.0%
Sector breakdown
Full portfolio 13 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| PSNL Personalis, Inc. - Common Stock | $188,202,236 | 35.75% | 14,044,943 | $98,735,949 | |||
| MRNA Moderna, Inc. - Common Stock | $161,642,545 | 30.71% | 2,308,190 | $44,386,493 | |||
| KYMR Kymera Therapeutics, Inc. - Common Stock | $88,544,161 | 16.82% | 772,165 | $24,230,538 | |||
| AKTS Aktis Oncology, Inc. - Common stock | $30,710,162 | 5.83% | 952,844 | $13,663,783 | |||
| EIKN Eikon Therapeutics, Inc. - Common Stock | $21,749,991 | 4.13% | 1,666,666 | $4,116,665 | |||
| TRDA Entrada Therapeutics, Inc. - Common Stock | $12,804,692 | 2.43% | 1,739,768 | Up ×1 | |||
| STRO Sutro Biopharma, Inc. - Common Stock | $9,042,053 | 1.72% | 272,351 | Up ×1 | |||
| ALEC Alector, Inc. - Common Stock | $7,126,896 | 1.35% | 3,545,719 | $-496,401 | |||
| EVAX Evaxion A/S - American Depositary Share | $3,763,791 | 0.71% | 1,214,126 | Up ×1 | |||
| VRDN Viridian Therapeutics, Inc. - Common Stock | $1,716,015 | 0.33% | 93,414 | $-111,163 | |||
| Unknown issuer (CUSIP: 98422T209) | $1,015,308 | 0.19% | 105,982 | $123,999 | |||
| HURA TuHURA Biosciences, Inc. - Common Stock | $45,501 | 0.01% | 19,445 | $10,694 | |||
| NEUP Neuphoria Therapeutics Inc. - Common Stock | $43,818 | 0.01% | 10,027 | $3,008 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| PSNL | Price move only | +0 | +$98.7M |
| MRNA | Price move only | +0 | +$44.4M |
| KYMR | Price move only | +0 | +$24.2M |
| AKTS | Price move only | +0 | +$13.7M |
| EIKN | Price move only | +0 | +$4.1M |
| ALEC | Price move only | +0 | -$496K |
| — | Price move only | +0 | +$124K |
| VRDN | Price move only | +0 | -$111K |
| HURA | Price move only | +0 | +$11K |
| NEUP | Price move only | +0 | +$3K |
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.